Overview
Novel Regimens in COVID-19 Treatment
Status:
Recruiting
Recruiting
Trial end date:
2030-12-01
2030-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tanta UniversityTreatments:
Azithromycin
Chloroquine
Ivermectin
Nitazoxanide
Criteria
Inclusion Criteria:- Patients with COVID-19 infection
Exclusion Criteria:
- Allergy or contraindication to the drugs.